Post-Market Pharmacovigilance

Following a discussion on data that demonstrated the use of trastuzumab in HER2-positive breast cancer, Hope S. Rugo, MD, remarks on the importance of conducting pharmacovigilance if the trastuzumab biosimilar becomes available as an approved product in the oncology space.
October 04, 2017
View Text Version

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.